Gambaro S E, Romero P, Pedraza N, Moulin L, Yantorno S, Ramisch D, Rumbo C, Barros-Schelotto P, Descalzi V, Gondolesi G E
Hepatology, HPB Surgery and Liver Transplantation Unit, Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina.
Hepatology, HPB Surgery and Liver Transplantation Unit, Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina; Instituto de Medicina Translacional, Trasplante y Bioingenieria, Universidad Favaloro-Conicet, Buenos Aires, Argentina.
Transplant Proc. 2017 Nov;49(9):2122-2128. doi: 10.1016/j.transproceed.2017.07.019.
Despite the progressively increasing gap between patients waiting for liver transplant under the Model for End-stage Liver Disease MELD system and the availability of deceased donor organs, the use of right extended split liver grafts (RESLG) has not been accepted by all centers. In this study, we compared the results obtained using RESLG vs a group of matched whole liver graft (WLG) recipients at a single center in Latin America.
A single-center retrospective review performed between August 2009 and December 2015.
Fifteen RESLGs were implanted to recipients between 13 and 70 years of age; 80% were performed ex situ. The "biological MELD" score for the RESLG group was 17.5 ± 5.6, and it was 12.8 ± 4.5 for the WLG group (P = .01). Cold ischemia times were significantly longer in RESLG recipients compared with WLG recipients (528 minutes vs 420 minutes; P < .01). No significant differences were found in biliary (leak or strictures P = .40) and arterial complications (hepatic artery thrombosis, P = .06). RESLG patients benefited from a considerable reduction on their waiting time in list. The 1-, 3-, and 5-year patient survival rates were 93%, 93%, and 93% respectively, for RESLG recipients vs 100%, 95.7%, and 86.1%, respectively, for WLG recipients. The 1-, 3-, and 5-year graft survival rates were 79.4%, 79.4%, and 79.4% for RESLG recipients and 89.7%, 89.7%, and 89.7% for WLG recipients, respectively. No statistical differences were observed.
RESLG allows expeditious transplantation for low MELD recipients. Its use should be expanded in Latin America and worldwide as a valid alternative to increase the donor pool as it has been used in other regions.
尽管在终末期肝病模型(MELD)系统下等待肝移植的患者与已故供体器官的可获得性之间的差距日益增大,但右半肝扩大劈裂式肝移植(RESLG)的应用尚未被所有中心所接受。在本研究中,我们比较了拉丁美洲一个单一中心使用RESLG与一组匹配的全肝移植(WLG)受者的结果。
2009年8月至2015年12月间进行的单中心回顾性研究。
15例RESLG植入13至70岁的受者;80%在体外进行。RESLG组的“生物MELD”评分为17.5±5.6,WLG组为12.8±4.5(P = 0.01)。与WLG受者相比,RESLG受者的冷缺血时间明显更长(528分钟对420分钟;P < 0.01)。在胆系(漏或狭窄,P = 0.40)和动脉并发症(肝动脉血栓形成,P = 0.06)方面未发现显著差异。RESLG患者在等待名单上的时间大幅缩短。RESLG受者的1年、3年和5年患者生存率分别为93%、93%和93%,而WLG受者分别为100%、95.7%和86.1%。1年、3年和5年移植物生存率RESLG受者分别为79.4%、79.4%和79.4%,WLG受者分别为89.7%、89.7%和89.7%。未观察到统计学差异。
RESLG可使低MELD评分受者快速接受移植。作为增加供体库的一种有效替代方法,其应用应在拉丁美洲及全球范围内扩大,因为它已在其他地区使用。